RepliCel Life Sciences Inc. announced that its board of directors has appointed Lee Buckler, formerly Vice President of Business and Corporate Development, as the company's new Chief Executive Officer and President, effective January 1, 2016. Mr. Buckler succeeds David Hall, who will retire as Chief Executive Officer at the end of the year after five years leading the company. The company also announced that effective January 1, 2016, David Hall will replace Peter Jensen, current Chairman of the Board, who will remain as a director.

Mr. Hall will also continue in an advisory capacity to the company as it focuses on its near and long-term business strategy. The Board also appointed Lee Buckler as a director, replacing the company's Chief Medical Officer, Dr. Rolf Hoffmann. This change in directorship enables Dr. Hoffmann to refocus his time on the advancement of RepliCel's clinical trials and the commercialization of its dermal injector device.

Lee has served as RepliCel's Vice President of Business and Corporate Development since October 2014.